Genexine, Inc.

KOSDAQ:A095700 Stock Report

Market Cap: ₩151.2b

Genexine Past Earnings Performance

Past criteria checks 0/6

There is insufficient data on Genexine's performance over the last few years.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs Industry Growth11.70%
Revenue growth raten/a
Return on equityn/a
Net Marginn/a
Last Earnings Update31 Mar 2024

Recent past performance updates

Analysis Article • Mar 19

Genexine (KOSDAQ:095700) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Genexine, Inc.'s ( KOSDAQ:095700 ) robust earnings report didn't manage to move the market for its stock. Our analysis...

Recent updates

Analysis Article • Jul 12

We Think Genexine (KOSDAQ:095700) Has A Fair Chunk Of Debt

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Analysis Article • Mar 14

Genexine (KOSDAQ:095700) Has Debt But No Earnings; Should You Worry?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analysis Article • Mar 19

Genexine (KOSDAQ:095700) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Genexine, Inc.'s ( KOSDAQ:095700 ) robust earnings report didn't manage to move the market for its stock. Our analysis...

Revenue & Expenses Breakdown

How Genexine makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSDAQ:A095700 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 245,808-54,52513,02926,548
31 Dec 234,427-66,87414,00826,330
30 Sep 235,200-107,82819,18233,093
30 Jun 237,224-105,68115,80029,553
31 Mar 236,019-96,28716,09626,661
31 Dec 2216,139-55,97415,91126,445
30 Sep 2215,807-50,55813,33028,044
30 Jun 2213,662-48,07412,33128,416
31 Mar 2214,678-52,95710,98631,184
31 Dec 2136,828-48,04210,14333,118
30 Sep 2143,3115849,28235,260
30 Jun 2143,74551,2428,84039,862
31 Mar 2143,80363,8168,43839,881
31 Dec 2018,54327,5707,99739,206
30 Sep 2013,752-4,0168,02338,286
30 Jun 2017,214-47,3258,42033,649
31 Mar 2018,290-61,2308,92838,480
31 Dec 1911,303-16,5099,15140,449

Quality Earnings: Insufficient data to determine if A095700 has high quality earnings.

Growing Profit Margin: Insufficient data to determine if A095700's profit margins have improved over the past year.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if A095700's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Insufficient data to compare A095700's past year earnings growth to its 5-year average.

Earnings vs Industry: Insufficient data to determine if A095700's earnings growth over the past year exceeded the Biotechs industry average.

Return on Equity

High ROE: A095700 has a negative Return on Equity (0%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/08/23 11:37
End of Day Share Price 2026/08/21 00:00
Earnings2024/03/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Genexine, Inc. is covered by 8 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ka-hye HongDaishin Securities Co. Ltd.
Hyerin LeeDAOL Investment & Securities Co., Ltd.
Ha Young KangDAOL Investment & Securities Co., Ltd.